- Home
- Service Center
It is estimated that the human genome encodes 15% of proteins that are considered to be disease-modifying. Only 2% of these proteins possess a druggable site that is approved as clinical candidate targets. Due to this disparity, there is an immense need to develop therapeutics that may better mitigate the diseases or disorders aroused by non-druggable and druggable proteins or enzymes. The recent surge in approved oligonucleotide therapeutics offers great potential for the treatment of these diseases or disorders.
As a dynamic pharmaceutical company in a vibrant life science research region, Alfa Chemistry leverages the expertise and experience of highly skilled, multi-disciplinary staff to provide development services for oligonucleotide therapeutics, including therapeutic ASO, siRNA, miRNA, aptamer, CpG oligonucleotide, DNAzyme, and transcription factor (TF) decoy. Our services primarily include target selection, sequence design, chemical synthesis, chemical modification, drug delivery, and non-clinical evaluation of oligonucleotide therapeutics. Our goal is to help you develop new oligonucleotide therapeutics and successfully bring them to market by optimizing existing methods or developing innovative technologies, benefitting patients worldwide. If you are also interested in the development of oligonucleotide therapeutics, please click on the link to learn more about our services. Let us work together to create a better world.
ASO is not only a useful tool for studying loss-of-gene function and target validation, but also has high value as a new therapeutic strategy for treating diseases associated with dysregulated gene expression.
Owing to specific and compelling gene silencing, siRNA is expected to become an essential approach to treating a variety of infectious, hematologic tumors, cardiovascular, and neurodegenerative conditions.
miRNA can modulate post-transcriptionally hundreds of downstream genes and has become an attractive tool and target for novel therapeutic approaches. Alfa Chemistry is committed to providing comprehensive miRNA development services to customers.
Alfa Chemistry provides customers with aptamer development services that are based on extensive experience and advanced technology, such as exponential enrichment (SELEX) technology.
Alfa Chemistry is passionate about developing innovative DNAzymes, which are related to the treatment of cancer, viral, asthma, cardiovascular, inflammatory, and central nervous system diseases.
Alfa Chemistry is committed to maximizing the value of CpG oligonucleotides for the prevention or treatment of diseases such as cancer, allergies and infectious diseases.
TF decoy technology has been proposed as an effective therapeutic tool against a variety of diseases such as different types of cancer, rheumatoid arthritis, atherosclerosis, heart failure, abdominal aortic aneurysm, Alzheimer’s disease, etc.
As a specialist in oligonucleotide therapeutics, Alfa Chemistry offers consumers a wealth of raw materials and a full range of technologies and services.
Privacy Policy | Cookie Policy | Copyright © 2025 Alfa Chemistry. All rights reserved.